A Study of S-892216 in Participants With COVID-19
← catalyst calendarSponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
282actual
Sites
57
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-06 | actual | When the study began enrolling |
| Primary completion | 2025-09-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-22 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Interventions
- Drug: S-892216
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in SARS-CoV-2 Viral RNA Level on Day 4 as Assessed by Quantitative Reverse-transcription Polymerase Chain Reaction (qRT-PCR) of Nasopharyngeal (NP) Swabs
measured Baseline through Day 4
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed